(IN BRIEF) Roche presented new data at ECTRIMS 2025 confirming that OCREVUS provides sustained protection against disability progression and maintains a consistent safety profile across multiple MS populations, including adults with advanced PPMS, children with RRMS, and women who are … Read the full press release
Posted in Healthcare, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged BTK inhibitor, disability progression, ECTRIMS 2025, fenebrutinib, FENhance, FENopta, FENtrepid, infant immunity, Levi Garraway, MINORE, MS, multiple sclerosis, neurofilament light chain, OCARINA II, ocrelizumab, OCREVUS, OPERETTA, ORATORIO-HAND, paediatric MS, PPMS, pregnancy outcomes, RMS, Roche, Roche presents late-breaking MS data including OCREVUS impact in pregnancy and two-year fenebrutinib Phase II outcomes, Roche showcases new OCREVUS and fenebrutinib data at ECTRIMS 2025 highlighting long-term efficacy and safety in MS, RRMS, SOPRANINO, Stephen L Hauser
(IN BRIEF) Roche presented promising 96-week data from the Phase II FENopta study, showing that its investigational drug, fenebrutinib, significantly reduced relapse rates and prevented disability progression in patients with relapsing multiple sclerosis (RMS). The study revealed an annualized relapse … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Bruton’s tyrosine kinase, BTK inhibitor, clinical data, clinical research, clinical trial, data, disability, disability progression, fenebrutinib, FENopta, Levi Garraway, multiple sclerosis, Phase II, relapse rates, relapsing multiple sclerosis, RMS, Roche, treatment
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?